Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells
Cardiovascular Therapeutics, 04/27/2012
Pepke W et al. – Bivalirudin is better than unfractionated heparin (UFH) in reducing periprocedural platelet activation. Moreover, thrombin–induced tissue factor (TF) expression is inhibited by bivalirudin. Thus, bivalirudin seems to be a better anticoagulant during percutaneous coronary intervention (PCI) than UFH.
